CL2018002438A1 - Method and composition for the treatment of cancer or a skin lesion using a vaccine. - Google Patents

Method and composition for the treatment of cancer or a skin lesion using a vaccine.

Info

Publication number
CL2018002438A1
CL2018002438A1 CL2018002438A CL2018002438A CL2018002438A1 CL 2018002438 A1 CL2018002438 A1 CL 2018002438A1 CL 2018002438 A CL2018002438 A CL 2018002438A CL 2018002438 A CL2018002438 A CL 2018002438A CL 2018002438 A1 CL2018002438 A1 CL 2018002438A1
Authority
CL
Chile
Prior art keywords
cancer
vaccine
treatment
composition
skin lesion
Prior art date
Application number
CL2018002438A
Other languages
Spanish (es)
Inventor
Tim Ioannides
Original Assignee
Hpvvax Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax Llc filed Critical Hpvvax Llc
Publication of CL2018002438A1 publication Critical patent/CL2018002438A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UN MÉTODO PARA TRATAR O REDUCIR LA INCIDENCIA DE RECURRENCIA DE CÁNCER, TUMORES BENIGNOS O LESIONES ASOCIADAS AL VPH, INCLUIDO EL CÁNCER DE PIEL, Y PARTICULARMENTE EL CARCINOMA DE CÉLULAS ESCAMOSAS (CCE) Y CARCINOMA DE CÉLULAS BASALES, MEDIANTE LA ADMINISTRACIÓN DE UNA O MÁS DOSIS DE VACUNA RECOMBINANTE DEL VPH A UN PACIENTE.A METHOD TO TREAT OR REDUCE THE INCIDENCE OF CANCER RECURRENCE, BENIGN TUMORS OR INJURIES ASSOCIATED WITH HPV, INCLUDING SKIN CANCER, AND PARTICULARLY THE CARCINOMA OF SCAMOUS CELLS (CCE) AND CARCINOMA OF A MEDIST BASIS DOSAGE OF HPV RECOMBINANT VACCINE TO A PATIENT.

CL2018002438A 2016-02-27 2018-08-24 Method and composition for the treatment of cancer or a skin lesion using a vaccine. CL2018002438A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06

Publications (1)

Publication Number Publication Date
CL2018002438A1 true CL2018002438A1 (en) 2019-01-04

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002438A CL2018002438A1 (en) 2016-02-27 2018-08-24 Method and composition for the treatment of cancer or a skin lesion using a vaccine.

Country Status (16)

Country Link
EP (1) EP3419661A4 (en)
JP (3) JP2019506435A (en)
KR (1) KR20180112043A (en)
CN (1) CN108883168A (en)
AU (1) AU2017223970B2 (en)
BR (1) BR112018067550A2 (en)
CA (1) CA3015519A1 (en)
CL (1) CL2018002438A1 (en)
CO (1) CO2018009205A2 (en)
HK (1) HK1256935A1 (en)
IL (1) IL261340B2 (en)
MX (1) MX2018010338A (en)
MY (1) MY194694A (en)
SG (1) SG11201807080UA (en)
WO (1) WO2017147475A1 (en)
ZA (1) ZA201805679B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127095B (en) * 2019-07-19 2024-04-09 神州细胞工程有限公司 Chimeric human papillomavirus 11-type L1 protein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2795906C (en) * 2009-04-13 2019-02-26 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
CN101890160B (en) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 Multivalent recombinant human papilloma virus vaccine and application thereof
CN102497880A (en) * 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 Novel human papillomavirus (HPV) protein constructs and their use in the prevention of HPV disease
CA2838387A1 (en) * 2011-06-06 2012-12-13 Chevron Phillips Chemical Company Lp Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
CA2866582A1 (en) * 2012-03-18 2013-09-26 Brigitte Desiree Alberte Colau Method of vaccination against human papillomavirus
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015054678A2 (en) * 2013-10-13 2015-04-16 The Board Of Trustees Of The University Of Arkanasas Human papilloma virus therapeutic vaccine
EP3094652B1 (en) * 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
AU2015335652B2 (en) * 2014-10-24 2020-07-02 Hpvvax, Llc. Cancer and skin lesion treatment

Also Published As

Publication number Publication date
SG11201807080UA (en) 2018-09-27
MY194694A (en) 2022-12-15
IL261340B1 (en) 2023-03-01
IL261340B2 (en) 2023-07-01
BR112018067550A2 (en) 2019-10-01
JP2019506435A (en) 2019-03-07
CN108883168A (en) 2018-11-23
EP3419661A4 (en) 2019-10-23
AU2017223970A1 (en) 2018-09-13
JP2021155448A (en) 2021-10-07
WO2017147475A1 (en) 2017-08-31
CO2018009205A2 (en) 2018-09-20
ZA201805679B (en) 2019-11-27
AU2017223970B2 (en) 2022-01-27
EP3419661A1 (en) 2019-01-02
JP2023110038A (en) 2023-08-08
MX2018010338A (en) 2018-11-09
HK1256935A1 (en) 2019-10-04
CA3015519A1 (en) 2017-08-31
IL261340A (en) 2018-11-29
KR20180112043A (en) 2018-10-11

Similar Documents

Publication Publication Date Title
CL2018000706A1 (en) Derivatives of pyrazolopyrimidine as btk inhibitors for the treatment of cancer.
AR102553A1 (en) COMBINATION THERAPY WITH OX40 UNION AGONISTS AND TIGIT INHIBITORS
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
JO3735B1 (en) Tetrasubstituted alkene compounds and their use
MX2018001755A (en) Smallpox vaccine for use in cancer treatment.
MX366294B (en) 17a,21-diesters of cortexolone for use in the treatment of tumors.
MA40458A (en) Methods of treating cervical cancer
CY1123501T1 (en) USE OF RESLIZUMAB IN THE TREATMENT OF MODERATE TO SEVERE EOSINOPHILIC ASTHMA
MX2020001727A (en) Combination therapy.
BR112018002530A2 (en) combinations and uses and treatments of these
MX2017006076A (en) Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme.
CY1119532T1 (en) (S) -PYRILDOL AND THE PHARMACEUTALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CL2019000846A1 (en) Therapeutic protein.
MX2017010341A (en) Cancer therapy with a parvovirus combined with bevacizumab.
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
CL2018002438A1 (en) Method and composition for the treatment of cancer or a skin lesion using a vaccine.
EA202191165A1 (en) ELACESTRANT IN COMBINATION WITH ABEMACYCLIBUS IN WOMEN WITH BREAST CANCER
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
MX2018002681A (en) AGENT FOR ENHANCING IMMUNITY TO CANCER BY USING Allergin-1 ANTAGONIST.
EA201792294A1 (en) COMBINED TREATMENT (OPTIONS) WITH THE USE OF SERIBANTUMAB
CL2017001008A1 (en) Use of a hpv vaccine composition to treat cancer and skin lesion.
EA201992852A1 (en) DOSAGE DIAGRAM FOR TESETAXEL AND CAPETSITABINE
PH12015502086A1 (en) Ablative immunotherapy
CO2023006083A2 (en) Composition and method for the treatment of cancer using a vaccine as a first therapeutic active ingredient in combination with a second active ingredient
AR110679A1 (en) TUMOR REMANENT INFILTRATING LYMPHOCYTES AND PREPARATION METHODS AND USES OF THE SAME